Dr. Olga Kovalenko, MD – Cleveland, OH
Daniel Johnson health
The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovaria
Belur Nagaraj, A, Knarr M, Sekhar S, Connor R, Joseph P, Kovalenko O, Fleming A, Surti A, Nurmemmedov E, Beltrame L Marchini S, Kahn M, Difeo A, Cancer Research, 4/2021Hyperhomocysteinemia and Pulmonary Embolism in a Young Male
Kovalenko O, Kassem AN, Jenkins M, Cureus, 2020Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
Belur Nagaraj A, Joseph P, Kovalenko O, Wang Q, Xu R, DiFeo A, Gynecol Oncol, 2018
